Conneally E, Bardy P, Eaves C J, Thomas T, Chappel S, Shpall E J, Humphries R K
Terry Fox Laboratory, B.C. Cancer Agency, Vancouver, Canada.
Blood. 1996 Jan 15;87(2):456-64.
Recombinant retroviruses offer many advantages for the genetic modification of human hematopoietic cells, although their use in clinical protocols has thus far given disappointing results. There is therefore an important need to develop new strategies that will allow effectively transduced primitive hematopoietic target populations to be both rapidly characterized and isolated free of residual nontransduced but biologically equivalent cells. To address this need, we constructed a murine stem cell virus (MSCV)-based retroviral vector containing the 228-bp coding sequence of the murine heat-stable antigen (HSA) and generated helper virus-free amphotropic MSCV-HSA producer cells by transfection of GP-env AM12 packaging cells. Light density and, in some cases, lineage marker-negative (lin-) normal human marrow or mobilized peripheral blood cells preactivated by exposure to interleukin-3 (IL-3), IL-6, and Steel factor in vitro for 48 hours were then infected by cocultivation with these MSCV-HSA producer cells for a further 48 hours in the presence of the same cytokines. Fluorescence-activated cell sorting (FACS) analysis of the cells 24 hours later showed 21% to 41% (mean, 27%) of those that were still CD34+ to have acquired the ability to express HSA. The extent of gene transfer to erythroid and granulopoietic progenitors (burst-forming unit-erythroid and colony-forming unit-granulocyte-macrophage), as assessed by the ability of these cells to form colonies of mature progeny in the presence of normally toxic concentrations of G418, averaged 11% and 12%, respectively, in 6 experiments. These values could be increased to 100% and 77%, respectively, by prior isolation of the CD34+HSA+ cell fraction and were correspondingly decreased to an average of 2% and 5%, respectively, in the CD34+HSA- cells. In addition, the extent of gene transfer to long-term culture-initiating cells (LTC-IC) was assessed by G418 resistance. The average gene transfer to LTC-IC-derived colony-forming cells in the unsorted population was < or = 7% in 4 experiments. FACS selection of the initially CD34+HSA+ cells increased this value to 86% and decreased it to 3% for the LTC-IC plated from the CD34+HSA- cells. Transfer of HSA gene expression to a phenotypically defined more primitive subpopulation of CD34+ cells, ie, those expressing little or no CD38, could also be shown by FACS analysis of infected populations 24 hours after infection. These findings underscore the potential use of retroviral vectors encoding HSA for the specific identification and non-toxic selection immediately after infection of retrovirally transduced populations of primitive human hematopoietic cells. In addition, such vectors should facilitate the subsequent tracking of their marked progeny using multiparameter flow cytometry.
重组逆转录病毒为人类造血细胞的基因改造提供了许多优势,尽管它们在临床方案中的应用迄今取得的结果令人失望。因此,迫切需要开发新的策略,以便能够快速鉴定并分离出有效转导的原始造血靶细胞群,且不含残留的未转导但生物学特性等同的细胞。为满足这一需求,我们构建了一种基于小鼠干细胞病毒(MSCV)的逆转录病毒载体,其包含小鼠热稳定抗原(HSA)的228 bp编码序列,并通过转染GP-env AM12包装细胞,生成了无辅助病毒的嗜性MSCV-HSA生产细胞。然后,将低密度以及在某些情况下经体外暴露于白细胞介素-3(IL-3)、IL-6和Steel因子预激活48小时的谱系标记阴性(lin-)正常人骨髓或动员的外周血细胞,与这些MSCV-HSA生产细胞在相同细胞因子存在的情况下共培养48小时进行感染。24小时后对细胞进行荧光激活细胞分选(FACS)分析显示,仍为CD34+的细胞中有21%至41%(平均为27%)获得了表达HSA的能力。通过这些细胞在正常毒性浓度的G418存在下形成成熟子代集落的能力评估,基因向红系和粒系祖细胞(红系爆式形成单位和粒-巨噬系集落形成单位)的转移程度在6次实验中平均分别为11%和12%。通过预先分离CD34+HSA+细胞组分,这些值可分别提高到100%和77%,而在CD34+HSA-细胞中则相应地分别降至平均2%和5%。此外,通过G418抗性评估基因向长期培养起始细胞(LTC-IC)的转移程度。在4次实验中,未分选群体中向LTC-IC衍生的集落形成细胞的平均基因转移率≤7%。对最初的CD34+HSA+细胞进行FACS分选后,对于从CD34+HSA-细胞接种的LTC-IC,该值提高到86%,而降低到3%。感染24小时后对感染群体进行FACS分析也表明,HSA基因表达已转移到表型明确的更原始的CD34+细胞亚群,即那些几乎不表达或不表达CD38的细胞。这些发现强调了编码HSA的逆转录病毒载体在原始人类造血细胞逆转录病毒转导群体感染后立即进行特异性鉴定和无毒选择方面的潜在用途。此外,此类载体应有助于随后使用多参数流式细胞术追踪其标记的子代。